Current Report Filing (8-k)
AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of
of Report (Date of earliest event reported): May 7, 2021
REGEN BIOPHARMA, INC.
name of small business issuer as specified in its
or other jurisdiction of incorporation or organization)
Employer Identification No.)
File No. 333-191725
S. Carson Street, Suite 4, Carson City, Nevada,
of Principal Executive Offices)
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
8.01 Other Events.
Biopharma, Inc. (the “Company”) has begun the process of reviving
patent applications of the Company filed with the United States
Patent and Trademark Office (“USPTO”) which have been classified as
abandoned by the USPTO.
services in connection with the abovementioned revival activities
are being provided by Marc Baumgartner of Baumgartner Patent Law.
Mr. Baumgartner has over 20 years of experience in the field of
intellectual property law.
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
May 7, 2021